Trevi Therapeutics' Series C Round

Trevi Therapeutics raised a round of funding on July 20, 2017.

Trevi Therapeutics is a development-stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and n…

Articles about Trevi Therapeutics' Series C Round: